Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab)

Rituximab is a chemeric murine/human anti-B lymphocyte antigen CD20 monoclonal antibody used in the treatment of rheumatoid arthritis resistant to treatment by one or more anti TNF-alpha therapies (1). The recommended dose for an efficient depletion of the B CD 20 lymphocytes in rheumatoid arthritis...

Full description

Bibliographic Details
Main Authors: V. Bruzzese, J. Pepe
Format: Article
Language:English
Published: PAGEPress Publications 2011-06-01
Series:Reumatismo
Online Access:http://www.reumatismo.org/index.php/reuma/article/view/454